Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of ac… Read more
Sandoz Group AG (SDZXF) - Net Assets
Latest net assets as of December 2025: $9.38 Billion USD
Based on the latest financial reports, Sandoz Group AG (SDZXF) has net assets worth $9.38 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($22.03 Billion) and total liabilities ($12.65 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.38 Billion |
| % of Total Assets | 42.6% |
| Annual Growth Rate | 4850.7% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 5288500.85 |
Sandoz Group AG - Net Assets Trend (2022–2025)
This chart illustrates how Sandoz Group AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sandoz Group AG (2022–2025)
The table below shows the annual net assets of Sandoz Group AG from 2022 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $9.38 Billion | +14.96% |
| 2024-12-31 | $8.16 Billion | -5.66% |
| 2023-12-31 | $8.65 Billion | +11218609.08% |
| 2022-12-31 | $77.14K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sandoz Group AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $9.38 Billion | 100.00% |
| Total Equity | $9.38 Billion | 100.00% |
Sandoz Group AG Competitors by Market Cap
The table below lists competitors of Sandoz Group AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Las Vegas Sands Corp
NYSE:LVS
|
$17.15 Billion |
|
HP Inc
NYSE:HPQ
|
$17.15 Billion |
|
Lululemon Athletica Inc.
NASDAQ:LULU
|
$17.16 Billion |
|
Ajinomoto Co., Inc.
F:AJI0
|
$17.16 Billion |
|
West Pharmaceutical Services Inc
NYSE:WST
|
$17.12 Billion |
|
Tyson Foods Inc
NYSE:TSN
|
$17.12 Billion |
|
Novonesis (Novozymes) A/S
CO:NSIS-B
|
$17.10 Billion |
|
Centene Corp
NYSE:CNC
|
$17.10 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sandoz Group AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,163,000,000 to 9,384,000,000, a change of 1,221,000,000 (15.0%).
- Net income of 914,000,000 contributed positively to equity growth.
- Dividend payments of 315,000,000 reduced retained earnings.
- Other factors increased equity by 622,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $914.00 Million | +9.74% |
| Dividends Paid | $315.00 Million | -3.36% |
| Other Changes | $622.00 Million | +6.63% |
| Total Change | $- | 14.96% |
Book Value vs Market Value Analysis
This analysis compares Sandoz Group AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.91x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 231068.50x to 1.91x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $0.00 | $41.36 | x |
| 2023-12-31 | $20.11 | $41.36 | x |
| 2024-12-31 | $18.95 | $41.36 | x |
| 2025-12-31 | $21.69 | $41.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sandoz Group AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.74%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.19%
- • Asset Turnover: 0.51x
- • Equity Multiplier: 2.35x
- Recent ROE (9.74%) is above the historical average (-4.75%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -29.64% | 0.00% | 93060.00x | 1.30x | $-30.57K |
| 2023 | 0.89% | 0.77% | 0.51x | 2.25x | $-787.50 Million |
| 2024 | 0.00% | 0.00% | 0.52x | 2.44x | $-816.30 Million |
| 2025 | 9.74% | 8.19% | 0.51x | 2.35x | $-24.40 Million |
Industry Comparison
This section compares Sandoz Group AG's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sandoz Group AG (SDZXF) | $9.38 Billion | -29.64% | 1.35x | $17.13 Billion |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |